Credit Suisse’s Titan Pharmaceuticals TTNP Stock Holding History

Credit Suisse’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,160	Closed	-$69K	–	4609
2021 Q1	$69K	Buy	+1,160	New	+$76.8K	﹤0.01%	4213
2016 Q4	–	Sell	-3	Closed	-$70K	–	4235
2016 Q3	$70K	Sell	3 -1	-25%	-$19.4K	﹤0.01%	3974
2016 Q2	$87K	Buy	+4	New	+$85.2K	﹤0.01%	4083

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's TTNP Position: Q2 2021 in Review

Credit Suisse sold out of Titan Pharmaceuticals (TTNP) in Q2 2021, closing a stake of 1,160 shares — an estimated $69K sold.

Credit Suisse first reported a position in TTNP in Q2 2016 and held it in 3 quarters. The position peaked at $87K in Q2 2016. 16 funds tracked by Wall St. Rank hold TTNP as of Q2 2021.

Credit Suisse reported no remaining Titan Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Credit Suisse sold 1,160 Titan Pharmaceuticals shares in Q2 2021, an estimated $69K.
Credit Suisse first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 3 quarters.
Credit Suisse's Titan Pharmaceuticals position peaked at $87K in Q2 2016.
16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.